|
ZNF317 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.92129686896692E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.18760001832641E-09 |
| Normal-vs-Stage2 |
5.86160000000113E-05 |
| Normal-vs-Stage3 |
2.37659999458018E-08 |
| Normal-vs-Stage4 |
1.47559999996716E-07 |
| Stage1-vs-Stage2 |
6.229200E-01 |
| Stage1-vs-Stage3 |
4.056400E-01 |
| Stage1-vs-Stage4 |
4.564400E-01 |
| Stage2-vs-Stage3 |
3.338800E-01 |
| Stage2-vs-Stage4 |
3.064000E-01 |
| Stage3-vs-Stage4 |
9.382400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.15899981121015E-10 |
| Normal-vs-AfricanAmerican |
7.437800E-04 |
| Normal-vs-Asian |
1.592160E-04 |
| Caucasian-vs-AfricanAmerican |
7.096000E-01 |
| Caucasian-vs-Asian |
2.153200E-01 |
| AfricanAmerican-vs-Asian |
6.029200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.14560000374908E-08 |
| Normal-vs-Female |
3.14310022453412E-10 |
| Male-vs-Female |
9.129000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.4078000027703E-08 |
| Normal-vs-Age(41-60Yrs) |
3.56789997546514E-09 |
| Normal-vs-Age(61-80Yrs) |
1.34909999838229E-08 |
| Normal-vs-Age(81-100Yrs) |
2.683000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.416800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.566600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.717400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.424400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.320000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.174200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.717600E-02 |
| Classical-VS-Follicular |
6.625800E-02 |
| Classical-VS-Other |
2.841600E-01 |
| Classical-VS-Normal |
2.08510000376805E-08 |
| Tall-VS-Follicular |
4.508800E-01 |
| Tall-VS-Other |
9.980400E-01 |
| Tall-VS-Normal |
5.76240000049744E-07 |
| Follicular-VS-Other |
6.863800E-01 |
| Follicular-VS-Normal |
4.76329999887781E-08 |
| Other-VS-Normal |
5.915500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.20429996267546E-09 |
| Normal-vs-N1 |
2.90180000028784E-07 |
| N0-vs-N1 |
3.161000E-01 |
|
|
